<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02091934</url>
  </required_header>
  <id_info>
    <org_study_id>Stanford IRB #29233</org_study_id>
    <nct_id>NCT02091934</nct_id>
  </id_info>
  <brief_title>Wavefront-guided PRK vs Wavefront-optimized PRK</brief_title>
  <official_title>A Prospective, Randomized Comparison of Fellow Eyes Undergoing Wavefront-guided PRK Versus Wavefront-optimized PRK Using the Alcon Allegretto Eye-Q 400 Excimer Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the results of PRKK surgery when using&#xD;
      wavefront-guided excimer laser treatment compared to wavefront optimized excimer laser&#xD;
      treatment in patients with nearsightedness with and without astigmatism&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a research study comparing the outcomes of PRK surgery for nearsightedness when using&#xD;
      the two different excimer laser technologies. Patients will have both eyes treated with the&#xD;
      Alcon WaveLight Allegretto excimer laser. You will be one of 50 sighted patients at Stanford&#xD;
      to undergo treatment in this clinical research trial. This will be a prospective, randomized,&#xD;
      research study in which up to 100 consecutive eyes scheduled to undergo excimer laser photo&#xD;
      refractive keratectomy (PRK) using one laser technology in the first eye and the second laser&#xD;
      technology in the fellow eye for the correction of myopia (nearsightedness) with or without&#xD;
      astigmatism will be enrolled. The choice of which eye receives the wavefront guided&#xD;
      technology and which eye receives the wavefront-optimized technology will be randomized prior&#xD;
      to enrollment. Randomization will be done according to a randomization schedule. You will not&#xD;
      know which eye is being treated with which each technology. The randomization will determine&#xD;
      only whether your right or left eye is treated with the wavefront guided technology. The&#xD;
      other eye will be treated with wavefront-optimized laser technology. You have a fifty percent&#xD;
      chance of having your left eye treated with custom wavefront guided technology as your right&#xD;
      eye. Subjects will undergo bilateral (both eyes at once) PRK treatments using the Alcon&#xD;
      WaveLight Allegretto excimer laser. All subjects will be followed for one year after the&#xD;
      vision correction procedure. Subjects scheduled to undergo PRK for the correction of myopia&#xD;
      (nearsightedness) with or without astigmatism will be screened for eligibility. Eligible&#xD;
      subjects will be examined preoperatively to establish a baseline for ocular condition (the&#xD;
      general health and glasses prescription of the eyes). Postoperatively, subjects will undergo&#xD;
      an ophthalmic evaluation (complete eye examination) at regular intervals as specified in this&#xD;
      protocol. Patients will complete questionnaires preoperatively and postoperatively evaluating&#xD;
      quality of vision and quality of life. Retreatments (a second operation on the same eye for&#xD;
      residual nearsightedness) will not be allowed during the first twelve months of this study.&#xD;
      If you elect to undergo a retreatment of your PRK surgery prior to the 12-month&#xD;
      post-operative visit, the retreated eye will be exited from the study as of the retreatment&#xD;
      date.&#xD;
&#xD;
      Any significant new finding developed during the course of the research which may relate to&#xD;
      the subject's willingness to continue participation will be provided to the subject or&#xD;
      subject's representative in a timely manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uncorrected visual acuity</measure>
    <time_frame>One year</time_frame>
    <description>Uncorrected visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Topographic analysis</measure>
    <time_frame>One year</time_frame>
    <description>Topographic analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wavefront analysis</measure>
    <time_frame>One year</time_frame>
    <description>Wavefront analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of vision and quality of life questionnaire</measure>
    <time_frame>One year</time_frame>
    <description>Patient Reported Outcomes Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal haze</measure>
    <time_frame>One year</time_frame>
    <description>Corneal haze</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in best corrected 5 and 25% contrast visual acuity</measure>
    <time_frame>One year</time_frame>
    <description>Changes in best corrected 5 and 25% contrast visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in best corrected visual acuity</measure>
    <time_frame>One year</time_frame>
    <description>Changes in best corrected visual acuity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refractive predictability</measure>
    <time_frame>One year</time_frame>
    <description>Refractive predictability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>Wavefront-guided PRK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wavefront-guided PRK</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wavefront-optimized PRK</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Wavefront-optimized PRK</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wavefront-guided PRK</intervention_name>
    <description>Wavefront-guided PRK</description>
    <arm_group_label>Wavefront-guided PRK</arm_group_label>
    <other_name>Alcon Wavelight Eye-Q 400 wavefront-guided PRK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wavefront-optimized PRK</intervention_name>
    <description>Wavefront-optimized PRK</description>
    <arm_group_label>Wavefront-optimized PRK</arm_group_label>
    <other_name>Alcon Wavelight Eye-Q 400 wavefront-optimized PRK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects age 21 and older with healthy eyes.&#xD;
&#xD;
          -  Nearsightedness between -0.25 diopters and -8.00 diopters with or without astigmatism&#xD;
             of up to 5.00 diopters.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects under the age of 21.&#xD;
&#xD;
          -  Excessively thin corneas.&#xD;
&#xD;
          -  Topographic evidence of keratoconus.&#xD;
&#xD;
          -  Ectactic eye disorders.&#xD;
&#xD;
          -  Autoimmune diseases.&#xD;
&#xD;
          -  Pregnant or nursing.&#xD;
&#xD;
          -  Patients must have similar levels of nearsightedness in each eye. They can not be more&#xD;
             than 2.5 diopter of difference between eyes.&#xD;
&#xD;
          -  Patients must have similar levels of astigmatism in each eye. They can not have more&#xD;
             than 1.5 diopter of difference between eyes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward E Manche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Eye Laser Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 9, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Edward E. Manche</investigator_full_name>
    <investigator_title>Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Alcon</keyword>
  <keyword>Wavelight</keyword>
  <keyword>PRK</keyword>
  <keyword>Wavefront-guided</keyword>
  <keyword>Wavefront-optimized</keyword>
  <keyword>Myopia</keyword>
  <keyword>Astigmatism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipivefrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

